Physician profile
Paul Le
NPI 1770766313
$26,511.03
in general payments reported to CMS, 2019-2025
43 companies · $2,347 in 2025
The $2,347 reported for 2025 was more than what 81% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,809 · 2020: $1,460 · 2021: $4,724 · 2022: $6,603 · 2023: $3,219 · 2024: $5,347 · 2025: $2,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,585.84 |
| Travel and Lodging | $328.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $14,054.87 | 2019-2025 | Proclaim, Octrode, Infinity |
| Boston Scientific Corporation | $4,667.91 | 2019-2025 | General - Pain Management |
| Medtronic, INC. | $1,781.49 | 2021-2025 | Synchromedii, Inceptiv, Primeadvanced Surescan |
| Abbvie INC. | $753.89 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $614.02 | 2019-2024 | Belbuca, Xtampza |
| Nalu Medical, INC. | $495.92 | 2024 | Nalu Neurostimulation System |
| Nevro Corp. | $459.70 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $359.36 | 2021-2024 | Relistor |
| Globus Medical, INC. | $337.19 | 2025 | Senza, Omnia |
| Pfizer INC. | $334.69 | 2019-2024 | |
| Lundbeck LLC | $271.05 | 2023-2024 | Vyepti |
| Amgen INC. | $216.05 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $193.86 | 2022 | |
| Novartis Pharmaceuticals Corporation | $176.91 | 2019-2021 | |
| Protega Pharmaceutials INC | $151.96 | 2025 | Roxybond |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.